Antibodies have long been used in biomedical science as in vitro tools
for the identification, purification and functional manipulation of t
arget antigens; they have been exploited in vivo for diagnostic and th
erapeutic applications as well. Recent advances in antibody engineerin
g have now Allowed the genes encoding antibodies to be manipulated so
that the antigen binding domain can be expressed intracellularly. The
specific and high-affinity binding properties of antibodies, combined
with their ability to be stably expressed in precise intracellular loc
ations inside mammalian cells, has provided a powerful new family of m
olecules for gene therapy applications. These intracellular antibodies
are termed 'intrabodies'. Two clinical protocols have been approved b
y the RAC for the use of intrabodies bodies in the treatment of an onc
ologic and an infectious disease. Their clinical use will in all likel
ihood become widespread if these initial studies show 'proof in princi
ple'. In this article, the studies from laboratories that have used in
trabodies as molecular reagents for cancer therapy and for the control
of infectious diseases will be reviewed and future directions of this
technology will be discussed.